8-K: MaxCyte Reports 2% Revenue Increase in Q3 2024, Core Business Up 23%

MaxCyte announced a 2% increase in total revenue and a 23% increase in core business revenue for the third quarter of 2024, alongside updated full-year guidance.

Summary

• MaxCyte reported a total revenue of $8.2 million for the third quarter of 2024, a 2% increase compared to the same period in 2023.
• Core business revenue, which excludes Strategic Platform License (SPL) program revenue, reached $8.1 million, a 23% increase year-over-year.
• Cell therapy revenue saw a significant 39% increase, reaching $6.5 million, while drug discovery revenue decreased by 14% to $1.6 million.
• SPL program-related revenue was negligible in Q3 2024, compared to $1.4 million in Q3 2023.
• The company signed six new SPL clients year-to-date, bringing the total to 29.
• MaxCyte's total cash, cash equivalents, and investments stood at $196.6 million as of September 30, 2024.
• The company has increased its full-year 2024 core business revenue guidance to at least 5% growth compared to 2023, while maintaining SPL program-related revenue guidance at approximately $6 million.
• The company is considering the costs and benefits of maintaining dual listings on AIM and Nasdaq, with a potential move to concentrate trading on Nasdaq.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with strong core revenue growth and increased guidance offset by a decrease in gross margin and a continued net loss. The overall sentiment is positive due to the core revenue growth and increased guidance, but there are some concerns that need to be addressed.

Positives

• Core business revenue showed strong growth of 23% in the third quarter of 2024.
• Cell therapy revenue experienced a substantial increase of 39% in the third quarter of 2024.
• The company has secured six new SPL clients year-to-date, demonstrating strong market interest.
• MaxCyte maintains a healthy cash balance of $196.6 million.
• The company has increased its full-year core business revenue guidance, indicating confidence in future performance.

Negatives

• Total revenue growth was only 2% in Q3 2024, despite strong core revenue growth.
• Drug discovery revenue declined by 14% in Q3 2024.
• SPL program-related revenue was immaterial in Q3 2024, a significant decrease from the previous year.
• Gross profit decreased to $6.2 million in Q3 2024, compared to $7.2 million in Q3 2023.
• Gross margin decreased to 76% in Q3 2024, compared to 90% in Q3 2023.
• The company reported a net loss of $11.6 million for Q3 2024, slightly higher than the $11.3 million loss in Q3 2023.

Risks

• The company's reliance on SPL partnerships for future revenue growth poses a risk if these partnerships do not materialize or perform as expected.
• The potential delisting from AIM could impact investor sentiment and trading volume.
• The decrease in drug discovery revenue could indicate a weakness in that segment of the business.
• The decrease in gross margin could impact profitability if not addressed.
• The company continues to operate at a loss, which could raise concerns about long-term financial sustainability.

Future Outlook

MaxCyte has increased its full-year 2024 core business revenue guidance to at least 5% growth compared to 2023 and maintains SPL program-related revenue guidance at approximately $6 million. The company expects to end 2024 with approximately $185 million in total cash, cash equivalents and investments.

Management Comments

• Maher Masoud, President and CEO, stated he is pleased with MaxCyte's financial performance in the third quarter and confident in the outlook for the remainder of 2024.
• Maher Masoud noted that the strong core revenue growth and increasing demand for the platform were driven by exceptional commercial execution and the value proposition of MaxCyte within the cell therapy industry.
• Management is prioritizing investments that will provide the best return on investment and long-term growth.
• The company is continuously evaluating and executing on opportunities to reduce its cost structure and improve operational focus and efficiency.

Industry Context

MaxCyte's results reflect the growing demand for cell engineering technologies in the cell therapy market. The company's focus on non-viral engineering approaches aligns with industry trends towards safer and more efficient cell modification methods. The increasing number of SPL partnerships indicates a strong market position and growing adoption of their technology.

Comparison to Industry Standards

• MaxCyte's 23% core revenue growth is strong compared to some of its peers in the cell therapy space, although direct comparisons are difficult due to varying business models.
• The company's 29 SPL partnerships are a significant achievement, indicating a strong market position compared to companies with fewer partnerships.
• The gross margin decrease from 90% to 76% is a concern and should be compared to other companies in the sector to assess if this is an industry-wide trend or specific to MaxCyte.
• The company's cash position of $196.6 million is healthy and provides a buffer for future operations and investments, which is a positive compared to companies with less cash on hand.
• The company's focus on non-viral engineering is in line with the industry trend away from viral vectors, which is a positive for long-term growth.

Stakeholder Impact

• Shareholders may react positively to the increased core revenue guidance and the strong growth in cell therapy revenue.
• Employees may be encouraged by the company's positive performance and future outlook.
• Customers will likely benefit from the company's continued investment in its platform and technology.
• Suppliers may see increased demand for their products and services as the company grows.
• Creditors may view the company's healthy cash balance as a positive sign of financial stability.

Next Steps

• The company will host a conference call on November 6, 2024, to discuss the financial results.
• The company is considering requesting shareholder approval to delist from AIM at the 2025 Annual Meeting of Shareholders.
• The company will continue to focus on growing its core business and expanding its SPL partnerships.

Key Dates

Keywords

cell therapy, strategic platform license, SPL, core revenue, revenue growth, electroporation, biotechnology, financial results, guidance, MaxCyte, ExPERT platform